Koncar Robert F, Feldman Rebecca, Bahassi El Mustapha, Hashemi Sadraei Nooshin
Department of Internal Medicine, Division of Hematology/Oncology, University of Cincinnati, Cincinnati, Ohio.
Caris Life Sciences, Phoenix, Arizona.
Cancer Med. 2017 Jul;6(7):1673-1685. doi: 10.1002/cam4.1108. Epub 2017 May 29.
Approximately 5% of all cancer incidences result from human papillomavirus (HPV) infection. HPV infection most commonly leads to cancers of the anogenital region or oropharynx. It is unknown whether different HPV-mediated cancers collectively share a molecular signature and it is important to determine if there are targetable alterations common to different types of HPV-positive tumors. We analyzed 743 p53 wild-type samples of anal, cervical, oropharyngeal, and vulvar squamous cell carcinomas which underwent multiplatform testing at a commercial molecular profiling service. Expression of 24 proteins was measured by immunohistochemistry (IHC), mutation of 48 genes was determined by next-generation and Sanger sequencing, and copy number alteration for six genes was determined by in situ hybridization. The four cohorts had remarkably similar molecular profiles. No gene had a statistically significant difference in mutation frequency or copy number change between the four different types of squamous cell carcinomas. The only significant differences between cohorts were frequency of ERCC1 and SPARC loss as determined by IHC. In all four cancer types, oncogene mutation and PD-L1 expression was relatively infrequent. The most commonly mutated gene was PIK3CA, with mutations most often affecting the helical domain of the protein and accompanied by concurrent lack of PTEN expression. Loss of MGMT and RRM1 was common among the four cohorts and may be predictive of response to cytotoxic therapies not currently being used to treat these cancer types. The similar molecular profiles of the four cohorts indicate that treatment strategies may be similarly efficacious across HPV-positive cancers.
所有癌症病例中约5%是由人乳头瘤病毒(HPV)感染引起的。HPV感染最常导致肛门生殖器区域或口咽癌。目前尚不清楚不同的HPV介导的癌症是否共同具有分子特征,确定不同类型的HPV阳性肿瘤是否存在可靶向改变非常重要。我们分析了743份肛门、宫颈、口咽和外阴鳞状细胞癌的p53野生型样本,这些样本在一家商业分子谱分析服务机构进行了多平台检测。通过免疫组织化学(IHC)检测24种蛋白质的表达,通过下一代测序和桑格测序确定48个基因的突变,并通过原位杂交确定6个基因的拷贝数改变。这四个队列具有非常相似的分子谱。在四种不同类型的鳞状细胞癌之间,没有基因在突变频率或拷贝数变化上有统计学显著差异。各队列之间唯一的显著差异是通过IHC确定的ERCC1和SPARC缺失频率。在所有四种癌症类型中,癌基因突变和PD-L1表达相对不常见。最常发生突变的基因是PIK3CA,其突变最常影响该蛋白的螺旋结构域,并伴有PTEN表达的同时缺失。MGMT和RRM1的缺失在这四个队列中很常见,可能预示着对目前未用于治疗这些癌症类型的细胞毒性疗法的反应。这四个队列相似的分子谱表明,治疗策略在HPV阳性癌症中可能同样有效。